NasdaqHealth CareHealth Care EquipmentS&P MidCap 400
$61.31
+3.25 (+5.60%)
Close of Nov 06, 2026 · end-of-day data
BRKR 8-K filings in 2025
Every material Form 8-K Bruker filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bruker Corporation's board increased its size by one seat to eleven directors and appointed Jack J. Phillips to fill the new seat, effective January 1, 2026. Phillips, a former Accelerate Diagnostics and Roche Diagnostics North America executive, will serve until the 2027 annual meeting, and the company says his diagnostics experience will support its infectious disease and specialty diagnostics efforts.
Board expanded to eleven directors; Phillips assigned to Class III and will serve until the 2027 Annual Meeting of Stockholders.
Phillips was President and CEO of Accelerate Diagnostics from 2020 to 2025 and President and CEO of Roche Diagnostics North America from 2010 to 2020.
Phillips' director compensation will match that of other non-employee directors, as described in the April 11, 2025 proxy statement.
Bruker will file an amended Form 8-K later to disclose his committee assignments.
Bruker reported third-quarter 2025 revenue of $860.5 million, down 0.5% from a year earlier, and a GAAP diluted loss of $(0.41) per share, which included $119.4 million of goodwill and intangible impairment charges and $34.5 million of restructuring charges. Non-GAAP diluted EPS was $0.45, compared with $0.60 a year earlier. The company lowered its FY2025 non-GAAP EPS outlook to $1.85 to $1.90, citing earlier market weakness and EPS dilution from a higher share count.
Q3 2025 revenue $860.5 million, down 0.5% year-over-year and down 4.5% organically
Q3 2025 GAAP diluted loss $(0.41) per share versus EPS of $0.27 a year earlier; non-GAAP diluted EPS $0.45 versus $0.60
FY2025 guidance: revenue $3.41 to $3.44 billion and non-GAAP EPS $1.85 to $1.90
FY2026 cost-savings initiatives of $100 to $120 million are progressing toward the high end of the target
Bruker reported second quarter 2025 revenue of $797.4 million, down 0.4% from a year earlier, and non-GAAP diluted EPS of $0.32, down 38.5%. The company lowered its FY 2025 non-GAAP EPS guidance to $1.95 to $2.05 from the prior range implied by its outlook, citing weak demand in academic, biopharma and industrial markets, plus tariffs and currency pressure. Shareholders face lower near-term profit expectations, partly offset by a planned cost program of $100 million to $120 million in annual savings for FY 2026.
Q2 2025 revenue $797.4 million, down 0.4% yoy; organic revenue down 7.0%
Q2 2025 non-GAAP diluted EPS $0.32 vs. $0.52 a year earlier; GAAP diluted EPS $0.05
FY 2025 guidance: revenue $3.43 to $3.50 billion and non-GAAP EPS $1.95 to $2.05, compared with $2.41 in FY 2024
Cost savings initiative expected to reduce annual costs by $100 million to $120 million in FY 2026
Bruker Corporation said preliminary second quarter 2025 revenue was $795-$798 million, roughly flat year-over-year, while non-GAAP organic revenue fell about 7%. Non-GAAP EPS is expected at $0.32-$0.34, a decline of about $0.19 per share that includes a $0.06 foreign currency headwind. The figures are unaudited and subject to quarter-end closing, and the company will report final results on August 4, 2025.
Preliminary Q2 2025 revenue of $795-$798 million, approximately flat reported year-over-year
Non-GAAP organic revenue declined about 7%; constant-exchange rate revenue declined about 3%
Non-GAAP EPS expected at $0.32-$0.34, about $0.19 per share lower year-over-year, including a $0.06 foreign currency headwind
Final results and earnings call scheduled for August 4, 2025, with the call at 8:30 a.m. EDT
At its May 29, 2025 annual meeting, Bruker's stockholders approved the Bruker Corporation 2026 Incentive Compensation Plan, which replaces the 2016 plan and reserves up to 12,000,000 shares for awards. The filing also reports that all four director nominees were elected and that stockholders approved the advisory say-on-pay vote and the ratification of PricewaterhouseCoopers LLP as auditor.
Plan authorizes up to 12,000,000 shares of common stock, including 6,000,000 new shares, and takes effect February 19, 2026, when the 2016 plan expires
Plan adoption approved with 90,071,055 votes for and 24,751,839 against, with 17,338,019 broker non-votes
Director Frank H. Laukien received 114,517,162 votes for; Richard A. Packer received 89,464,768 votes for and 38,597,851 withheld
PricewaterhouseCoopers LLP ratified as auditor for fiscal 2025 with 131,634,268 votes for
Bruker reported first quarter 2025 revenue of $801.4 million, up 11.0% year over year, but non-GAAP diluted EPS fell 11.3% to $0.47 and GAAP diluted EPS was $0.11, down from $0.35. The company lowered its full-year 2025 organic revenue growth and non-GAAP EPS guidance, citing academic market and tariff dynamics, which points to a weaker profit outlook for shareholders.
Bruker Corporation said in an 8-K that preliminary first-quarter 2025 revenue for the period ended March 31, 2025 is expected to be $795 million to $800 million, which the company says compares favorably with its earlier outlook and consensus. The figures are unaudited, have not been reviewed by the independent auditor, and could change during quarter-end closing, so the company warns that undue reliance should not be placed on them. Final first-quarter results are scheduled for May 7, 2025.
Preliminary Q1 2025 revenue range: $795 million to $800 million, implying reported growth of about 10% year over year
Estimated non-GAAP organic revenue growth in the low-single digit percentages, with mid-single digit growth in the BSI segment and a high-teens percentage decline in the BEST segment
Final first-quarter 2025 results to be released before market opening on May 7, 2025, with a conference call at 8:30 a.m. Eastern Daylight Time
Bruker Corporation's Board increased its size by one seat to ten directors and appointed Laura Francis, CEO of SI-BONE, Inc., to fill the new vacancy effective February 18, 2025. The filing says she will join the Audit Committee after the 2025 annual meeting and that her director pay will match other non-employee directors.
Laura Francis appointed director effective February 18, 2025, serving until the 2026 Annual Meeting of Stockholders
Board expanded from nine to ten directors, with the new seat assigned to Class II
Francis expected to join the Audit Committee as a financial expert after the end of May 2025 annual meeting
Francis is CEO and a board member of SI-BONE, Inc. (Nasdaq: SIBN) and previously served as Bruker's CFO-era executive in an earlier career
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bruker filing is on SEC EDGAR ↗. 8-K briefs of other companies →